Emergence of fluoroquinolone-resistant tuberculosis in New York City

E. A. Sullivan; L. Palumbo; A. Ebrahimzadeh; T. R. Frieden; E. A. Sullivan; T. R. Frieden; B. N. Kreiswirth; V. Kapur; J. M. Musser

doi:10.1016/S0140-6736(95)90980-X

Emergence of fluoroquinolone-resistant tuberculosis in New York City

E. A. Sullivan, L. Palumbo, A. Ebrahimzadeh, T. R. Frieden, E. A. Sullivan, T. R. Frieden, B. N. Kreiswirth, V. Kapur, J. M. Musser

Research output: Contribution to journal › Article › peer-review

119 Scopus citations

Abstract

22 patients infected with fluoroquinolone-resistant Mycobacterium tuberculosis in New York City were identified between January, 1991, and November, 1993. In 16 patients resistance arose as a result of inadequate or inappropriate treatment. 6 patients had primary infection with fluoroquinolone-resistant organisms; 5 acquired the organisms nosocomially. Seven distinct patterns of restriction-fragment length polymorphism were identified in isolates from 21 patients. Fluoroquinolones should be restricted to patients with multidrug-resistant disease or intolerance to other antituberculosis drugs. All patients with multidrug-resistant tuberculosis should be on directly observed therapy.

Original language	English (US)
Pages (from-to)	1148-1150
Number of pages	3
Journal	The Lancet
Volume	345
Issue number	8958
DOIs	https://doi.org/10.1016/S0140-6736(95)90980-X
State	Published - May 6 1995

All Science Journal Classification (ASJC) codes

Medicine(all)

Access to Document

10.1016/S0140-6736(95)90980-X

Cite this

@article{45794472623a4dd48892f7735fd74a47,

title = "Emergence of fluoroquinolone-resistant tuberculosis in New York City",

abstract = "22 patients infected with fluoroquinolone-resistant Mycobacterium tuberculosis in New York City were identified between January, 1991, and November, 1993. In 16 patients resistance arose as a result of inadequate or inappropriate treatment. 6 patients had primary infection with fluoroquinolone-resistant organisms; 5 acquired the organisms nosocomially. Seven distinct patterns of restriction-fragment length polymorphism were identified in isolates from 21 patients. Fluoroquinolones should be restricted to patients with multidrug-resistant disease or intolerance to other antituberculosis drugs. All patients with multidrug-resistant tuberculosis should be on directly observed therapy.",

author = "Sullivan, {E. A.} and L. Palumbo and A. Ebrahimzadeh and Frieden, {T. R.} and Sullivan, {E. A.} and Frieden, {T. R.} and Kreiswirth, {B. N.} and V. Kapur and Musser, {J. M.}",

year = "1995",

month = may,

day = "6",

doi = "10.1016/S0140-6736(95)90980-X",

language = "English (US)",

volume = "345",

pages = "1148--1150",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "8958",

}

TY - JOUR

T1 - Emergence of fluoroquinolone-resistant tuberculosis in New York City

AU - Sullivan, E. A.

AU - Palumbo, L.

AU - Ebrahimzadeh, A.

AU - Frieden, T. R.

AU - Sullivan, E. A.

AU - Frieden, T. R.

AU - Kreiswirth, B. N.

AU - Kapur, V.

AU - Musser, J. M.

PY - 1995/5/6

Y1 - 1995/5/6

N2 - 22 patients infected with fluoroquinolone-resistant Mycobacterium tuberculosis in New York City were identified between January, 1991, and November, 1993. In 16 patients resistance arose as a result of inadequate or inappropriate treatment. 6 patients had primary infection with fluoroquinolone-resistant organisms; 5 acquired the organisms nosocomially. Seven distinct patterns of restriction-fragment length polymorphism were identified in isolates from 21 patients. Fluoroquinolones should be restricted to patients with multidrug-resistant disease or intolerance to other antituberculosis drugs. All patients with multidrug-resistant tuberculosis should be on directly observed therapy.

AB - 22 patients infected with fluoroquinolone-resistant Mycobacterium tuberculosis in New York City were identified between January, 1991, and November, 1993. In 16 patients resistance arose as a result of inadequate or inappropriate treatment. 6 patients had primary infection with fluoroquinolone-resistant organisms; 5 acquired the organisms nosocomially. Seven distinct patterns of restriction-fragment length polymorphism were identified in isolates from 21 patients. Fluoroquinolones should be restricted to patients with multidrug-resistant disease or intolerance to other antituberculosis drugs. All patients with multidrug-resistant tuberculosis should be on directly observed therapy.

UR - http://www.scopus.com/inward/record.url?scp=0029061114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029061114&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(95)90980-X

DO - 10.1016/S0140-6736(95)90980-X

M3 - Article

C2 - 7723548

AN - SCOPUS:0029061114

VL - 345

SP - 1148

EP - 1150

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8958

ER -

Emergence of fluoroquinolone-resistant tuberculosis in New York City

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this